Total Payments
$653,475
2023 Payments
$20,471
Companies
23
Transactions
1,195
Medicare Patients
1,203
Medicare Billing
$95,371
Payment Breakdown by Category
Other$273,067 (41.8%)
Consulting$217,787 (33.3%)
Travel$93,439 (14.3%)
Research$43,422 (6.6%)
Food & Beverage$25,661 (3.9%)
Gifts$79.40 (0.0%)
Education$20.88 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $217,787 | 121 | 33.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $205,542 | 76 | 31.5% |
| Travel and Lodging | $93,439 | 443 | 14.3% |
| Honoraria | $66,239 | 26 | 10.1% |
| Unspecified | $43,422 | 4 | 6.6% |
| Food and Beverage | $25,661 | 518 | 3.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,200 | 1 | 0.2% |
| Entertainment | $86.84 | 1 | 0.0% |
| Gift | $79.40 | 2 | 0.0% |
| Education | $20.88 | 3 | 0.0% |
Payments by Type
General
$610,054
1,191 transactions
Research
$43,422
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $210,031 | 518 | $0 (2021) |
| Shire North American Group Inc | $131,097 | 325 | $0 (2019) |
| Sun Pharmaceutical Industries Inc. | $55,373 | 70 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $52,238 | 69 | $0 (2021) |
| Dompe US, Inc. | $49,018 | 19 | $0 (2023) |
| Lumenis, Inc | $41,818 | 3 | $0 (2020) |
| Sight Sciences, Inc. | $34,486 | 47 | $0 (2021) |
| MacuLogix, Inc. | $27,538 | 25 | $0 (2020) |
| Kala Pharmaceuticals, Inc. | $18,073 | 26 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $13,894 | 40 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $20,471 | 1 | Dompe US, Inc. ($20,471) |
| 2022 | $4,250 | 1 | Dompe US, Inc. ($4,250) |
| 2021 | $40,077 | 53 | Kala Pharmaceuticals, Inc. ($14,912) |
| 2020 | $86,417 | 85 | Novartis Pharmaceuticals Corporation ($30,717) |
| 2019 | $203,578 | 359 | Shire North American Group Inc ($73,126) |
| 2018 | $141,014 | 277 | Shire North American Group Inc ($57,896) |
| 2017 | $157,668 | 419 | Allergan Inc. ($143,068) |
All Payment Transactions
1,195 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/14/2023 | Dompe US, Inc. | — | — | Cash or cash equivalent | $20,471.00 | Research |
| Study: Identification of Neurotropic Keratitis in a Previously Diagnosed Ocular Surface Disease Patient Population | ||||||
| 01/12/2022 | Dompe US, Inc. | OXERVATE (Drug) | Consulting Fee | Cash or cash equivalent | $4,250.00 | General |
| Category: SOLUTION/ DROPS | ||||||
| 09/23/2021 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $22.45 | General |
| 09/02/2021 | Allergan, Inc. | RESTASIS MULTIDOSE (Drug) | Food and Beverage | In-kind items and services | $81.99 | General |
| Category: DRY EYE | ||||||
| 07/23/2021 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $58.00 | General |
| 05/18/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Ocular | ||||||
| 05/18/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | Cash or cash equivalent | $54.00 | General |
| Category: Ocular | ||||||
| 05/11/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Ocular | ||||||
| 05/11/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Ocular | ||||||
| 05/11/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | Cash or cash equivalent | $409.49 | General |
| Category: Ocular | ||||||
| 05/11/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | Cash or cash equivalent | $124.35 | General |
| Category: Ocular | ||||||
| 05/11/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | Cash or cash equivalent | $49.34 | General |
| Category: Ocular | ||||||
| 05/11/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Food and Beverage | Cash or cash equivalent | $22.98 | General |
| Category: Ocular | ||||||
| 05/06/2021 | Allergan, Inc. | RESTASIS MULTIDOSE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,188.00 | General |
| Category: DRY EYE | ||||||
| 04/30/2021 | Allergan, Inc. | RESTASIS MULTIDOSE (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: DRY EYE | ||||||
| 04/30/2021 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug), EYSUVIS | Food and Beverage | In-kind items and services | $3.26 | General |
| Category: Ocular | ||||||
| 04/22/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | In-kind items and services | $362.71 | General |
| Category: Ocular | ||||||
| 04/22/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | In-kind items and services | $144.48 | General |
| Category: Ocular | ||||||
| 04/22/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Ocular | ||||||
| 04/22/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: Ocular | ||||||
| 04/21/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | In-kind items and services | $377.58 | General |
| Category: Ocular | ||||||
| 04/17/2021 | Allergan, Inc. | RESTASIS MULTIDOSE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,487.50 | General |
| Category: DRY EYE | ||||||
| 04/15/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | In-kind items and services | $450.72 | General |
| Category: Ocular | ||||||
| 04/15/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Travel and Lodging | In-kind items and services | $383.07 | General |
| Category: Ocular | ||||||
| 04/15/2021 | Kala Pharmaceuticals, Inc. | EYSUVIS (Drug) | Food and Beverage | In-kind items and services | $118.17 | General |
| Category: Ocular | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Identification of Neurotropic Keratitis in a Previously Diagnosed Ocular Surface Disease Patient Population | Dompe US, Inc. | $20,471 | 1 |
| Clinical Outcomes of the Recombinant Human Nerve Growth Factor (rhNGF) treatment for Stage 1 Neurotrophic Keratopathy | Dompe US, Inc. | $17,201 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH XIIDRA RESEARCH | Novartis Pharmaceuticals Corporation | $5,250 | 1 |
| Eye Health Inflammadry | Quidel Corporation | $500.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 11 | 521 | 592 | $71,421 | $31,842 |
| 2020 | 15 | 682 | 856 | $119,665 | $63,529 |
Total Patients
1,203
Total Services
1,448
Medicare Billing
$95,371
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 120 | 120 | $17,880 | $9,123 | 51.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 60 | 81 | $10,449 | $5,289 | 50.6% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 61 | 86 | $10,406 | $4,918 | 47.3% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 30 | 30 | $5,100 | $3,244 | 63.6% |
| 92250 | Photography of the retina | Office | 2021 | 100 | 104 | $10,296 | $2,736 | 26.6% |
| 92083 | Measurement of field of vision during daylight conditions, extended examination | Office | 2021 | 41 | 48 | $6,288 | $2,407 | 38.3% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2021 | 53 | 56 | $5,096 | $1,518 | 29.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 15 | $2,295 | $1,153 | 50.2% |
| 92284 | Evaluation of eye adaptation to light and dark (rods and cones) | Office | 2021 | 11 | 17 | $1,530 | $820.80 | 53.6% |
| 92285 | Photography of content of eyes | Office | 2021 | 19 | 24 | $1,080 | $338.98 | 31.4% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 11 | 11 | $1,001 | $293.36 | 29.3% |
| 65778 | Insertion of amniotic membrane to eye surface | Office | 2020 | 11 | 17 | $27,200 | $21,025 | 77.3% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2020 | 146 | 146 | $21,754 | $12,659 | 58.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 84 | 154 | $19,866 | $8,290 | 41.7% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2020 | 50 | 77 | $9,317 | $5,186 | 55.7% |
| 92250 | Photography of the retina | Office | 2020 | 138 | 140 | $13,860 | $4,606 | 33.2% |
| 92083 | Measurement of field of vision during daylight conditions | Office | 2020 | 41 | 50 | $6,550 | $2,544 | 38.8% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2020 | 24 | 24 | $4,080 | $2,111 | 51.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 21 | 23 | $3,519 | $2,094 | 59.5% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2020 | 53 | 69 | $6,279 | $1,987 | 31.6% |
| 92285 | Photography of content of eyes | Office | 2020 | 29 | 42 | $1,867 | $772.38 | 41.4% |
| 92284 | Evaluation of eye adaptation to light and dark (rods and cones) | Office | 2020 | 15 | 19 | $1,710 | $769.32 | 45.0% |
| 83516 | Analysis of substance using immunoassay technique | Office | 2020 | 25 | 50 | $1,200 | $574.66 | 47.9% |
| 92134 | Diagnostic imaging of retina | Office | 2020 | 15 | 15 | $1,365 | $430.03 | 31.5% |
| 92020 | Examination of cornea and iris using lens device and slit lamp | Office | 2020 | 14 | 14 | $714.00 | $330.68 | 46.3% |
About Dr. Scott Schachter, O.D
Dr. Scott Schachter, O.D is a Optometrist healthcare provider based in Pismo Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447230602.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Schachter, O.D has received a total of $653,475 in payments from pharmaceutical and medical device companies, with $20,471 received in 2023. These payments were reported across 1,195 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($217,787).
As a Medicare-enrolled provider, Schachter has provided services to 1,203 Medicare beneficiaries, totaling 1,448 services with total Medicare billing of $95,371. Data is available for 2 years (2020–2021), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Optometrist
- Other Specialties Corneal and Contact Management
- Location Pismo Beach, CA
- Active Since 01/21/2006
- Last Updated 11/15/2012
- Taxonomy Code 152W00000X
- Entity Type Individual
- NPI Number 1447230602
Products in Payments
- XIIDRA (Drug) $164,163
- RESTASIS (Drug) $65,783
- CEQUA (Drug) $46,712
- TearCare (Device) $33,986
- AdaptDx (Device) $19,575
- EYSUVIS (Drug) $16,794
- RESTASIS MULTIDOSE (Drug) $10,746
- OXERVATE (Drug) $8,416
- ULTRA (Device) $7,378
- BIOTRUE ONE DAY (Device) $6,730
- BromSite (bromfenac ophthalmic solution) 0.075% (Drug) $6,211
- DAILIES (Device) $5,360
- Eye Health (Device) $4,639
- ALPHAGAN P (Drug) $3,443
- Oxervate (Drug) $2,931
- CEQUA (cyclosporine ophthalmic solution) 0.09% (Drug) $2,450
- Prokera (Device) $2,426
- Systane (Drug) $2,054
- INFUSE (Device) $1,200
- ILUX (Device) $1,060
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.